Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

Healthcare Deal Proceeds Calculator: From Headline Price to Cash at Close

Cash at close is headline enterprise value, less net debt, plus or minus the working-capital adjustment, minus transaction costs, rollover, any earnout inside the headline and escrow. In our worked $6M EBITDA example, a $52.8M headline pays $27.26M at closing, 51.6% of the price in the LOI. Sellers who compare offers on the multiple routinely pick the one that pays less at closing. Enter your LOI terms below and compare offers in dollars.

Data as of November 20, 2026. Market figures come from SRS Acquiom's 2026 escrow report (all industries), PESP's 2025 healthcare PE deal review, Bain's Global Healthcare Private Equity Report 2026, FOCUS Investment Banking's 2026 dermatology benchmarks, Kaufman Hall's Q3 2026 M&A report (October 13, 2026) and the CMS National Health Expenditure fact sheet (2024 data). Every multiple, escrow rate and earnout probability in the worked examples is an illustrative assumption, and every derived figure is our arithmetic.

Estimate only. Educational, not investment advice.

What You Enter and What You Get Back

You enter (inputs) The calculator returns (outputs)
Adjusted EBITDA and multiple Headline EV
Earnout face value and placement (inside or on top) Guaranteed EV
Net debt and working-capital adjustment Equity value
Transaction costs, rollover % and rollover base Cash at close, in dollars and as a share of headline
Escrow % and escrow base Rollover at cost, reported on its own line
Expected escrow release and earnout probability Expected cash, undiscounted

Five default settings. Each one can move the result by millions. Check them before you read any output.

Setting Default What it changes When to override
Earnout placement Inside the headline Lines 2 and 4: the earnout comes out of guaranteed price and cash at close Your LOI says the earnout is paid "plus" or "on top of" the price
Escrow base Headline EV Line 4: escrow dollars Your purchase agreement applies the rate to guaranteed EV, equity value or closing cash
Rollover base Equity value Lines 4 and 6: the split between cash and rolled equity Your LOI states rollover as a share of EV
Expected cash Undiscounted Line 5 only Never treat it as a forecast or a valuation. It is scenario math
Taxes Excluded Every output is pre-tax Model taxes separately with your tax adviser, because rollover and earnout treatment depends on structure

The fields interact. Moving the earnout from inside the headline to on top of it changes the guaranteed price, the escrow dollars and the rollover dollars. When you change one input, rerun the others.

8 Inputs That Move Your Proceeds

  1. EBITDA. Use the adjusted EBITDA the buyer accepted in the LOI, not your best case. Every rejected dollar costs you the full multiple. At 8.8x, a $250K add-back struck in diligence removes $2.2M of headline value. If you lack a defensible figure, start with the practice valuation calculator and the quality of earnings prep checklist.
  2. Multiple. Use your LOI multiple. EBITDA times the multiple is the headline EV, the price written in the LOI.
  3. Net debt. Debt paid off from proceeds at closing (bank loans, equipment financing, lines of credit the buyer does not assume), less cash you keep. Many practices carry loans under the SBA 7(a) program, the SBA's main small business loan program. List every outstanding balance on the payoff schedule. With a 20% rollover measured on equity value, each $1.00 of net debt cuts cash at close by $0.80 and rollover by $0.20.
  4. Working-capital adjustment. The gap between the working capital you deliver and the peg in your purchase agreement, positive or negative. Adjustments are the norm, not the exception (frequencies in the escrow section). The worked example uses $0 to isolate the other lines, so plan for a real number in your own case.
  5. Transaction costs. Your actual legal, accounting and advisory quotes, plus your share of any reps and warranties insurance (RWI) premium and any regulatory filing cost. Taxes do not go here. If an adviser charging a success fee runs your sale, look up the firm and the individual banker on FINRA BrokerCheck, the free lookup of registration and disclosure history, before you sign the engagement letter. The guide to choosing a healthcare investment banker covers who can be paid to sell a company, and questions on that point belong with your own attorney.
  6. Rollover %. The equity you reinvest in the buyer or its platform, applied to equity value by default. Some LOIs state it as a share of EV. Rollover appears at cost on its own line and is never added to cash.
  7. Earnout face value, placement and probability. Enter the maximum earnout, whether the headline contains it and the share you expect to collect. The calculator does not discount for time.
  8. Escrow % and expected release. Use the rate and base in your LOI, and run at least one case with release below 100%.

The Proceeds Formula in 7 Lines

1. Headline EV = EBITDA x multiple (the price written in the LOI) 2. Guaranteed EV = headline EV - earnout face value, if the earnout is inside the headline = headline EV, if the earnout sits on top 3. Equity value = headline EV - net debt +/- working-capital adjustment 4. Cash at close = equity value - transaction costs - rollover (rollover % x equity value, or x EV if your LOI says so) - earnout face value (only if it is inside the headline) - escrow (escrow % x headline EV, or x guaranteed EV if you switch the base) 5. Expected cash = cash at close (undiscounted) + escrow x share you expect back + earnout face value x your probability 6. Rollover at cost = the line 4 rollover amount, illiquid, reported separately 7. Cash-at-close ratio = cash at close / headline EV

These are modeling conventions. Your purchase agreement defines purchase price, closing payment and adjustments in its own words, and those words control. "Equity value" here still contains any earnout inside the headline, which is why line 4 removes it again. Four definitions drive most disputes between seller and buyer.

Headline vs contingent consideration. "$52.8M including up to $5.0M of earnout" means a guaranteed price of $47.8M, or 7.97x on $6.0M of EBITDA. "$52.8M plus up to $5.0M of earnout" means a guaranteed $52.8M and a maximum of $57.8M. Both get summarized as "8.8x." They are different deals.

Escrow base. When the earnout sits inside the headline, applying the escrow rate to headline EV holds back money against $5.0M you may never receive. At 10.0%, escrow is $5.28M on headline EV, $4.88M on the $48.8M equity value and $4.78M on the $47.8M guaranteed EV. The base is negotiable, and guaranteed EV is the cleanest ask.

Rollover base. A 20% rollover on equity value reinvests on value that is partly contingent. In the example below, 20% of equity is $9.76M and 20% of EV is $10.56M. That one definition moves $0.80M from cash into illiquid equity. Ask whether rollover is computed before or after the earnout comes out.

Expected cash is scenario math. Line 5 ignores the time value of money and is not a valuation. Line 6 stays separate because rolled equity cannot pay a tax bill.

Worked Example: $6M EBITDA Practice, $52.8M Headline

Assumptions (illustrative, not benchmarks): a multi-specialty practice with $6.0M of EBITDA priced at 8.8x. $4.0M of net debt paid off at closing, $0 working-capital adjustment, $1.5M of transaction costs, 20% rollover on equity value, a $5.0M earnout inside the headline and a 10.0% escrow on headline EV. After closing: full escrow release and a 50% chance of collecting the earnout. All figures are pre-tax and are our arithmetic.

Step Amount Running total Share of headline What the line is
Headline EV ($6.0M x 8.8x), earnout inside $52.80M $52.80M 100.0% Price written in the LOI
Less net debt paid at closing -$4.00M $48.80M 92.4% Loans settled from proceeds
Working-capital adjustment $0.00M $48.80M 92.4% Equity value
Less transaction costs -$1.50M $47.30M 89.6% Legal, accounting, advisory
Less rollover (20% x $48.80M) -$9.76M $37.54M 71.1% Reinvested, illiquid, carried at cost
Less earnout face value -$5.00M $32.54M 61.6% Contingent, paid later if earned
Less escrow (10.0% x $52.80M) -$5.28M $27.26M 51.6% Cash at close (4.54x EBITDA)
Plus escrow released (100% assumed) +$5.28M $32.54M 61.6% Cash after release, earnout excluded
Plus earnout x 50% probability +$2.50M $35.04M 66.4% Expected cash, undiscounted (5.84x EBITDA)
Rollover at cost, separate line $9.76M not added 18.5% Equity you cannot sell until the platform exits

Expected cash plus rollover is $44.80M, a mixed total of cash and illiquid stock. It is not a single number you can spend.

Stress test 1: escrow claim. If an indemnification claim consumes a quarter of the escrow, release falls from $5.28M to $3.96M and expected cash falls from $35.04M to $33.72M.

Stress test 2: working-capital shortfall. A $500K shortfall lowers equity value from $48.80M to $48.30M. Because rollover is 20% of equity value, rollover falls by $100K to $9.66M and cash at close falls by $400K to $26.86M. Escrow on headline EV does not change. The shortfall costs you the full $500K, split $400K in cash and $100K in rolled equity. If your LOI fixes rollover as a share of EV, the whole $500K comes out of cash at close.

Stress test 3: rollover on EV. Apply the 20% to the $52.80M headline instead of equity value. Rollover rises to $10.56M, cash at close falls to $26.46M and expected cash (full escrow back, earnout at 50%) falls from $35.04M to $34.24M.

The same deal under different escrow and rollover terms (illustrative rates, our arithmetic):

Variation Escrow held Rollover Cash at close Share of headline
10.0% on headline EV, rollover on equity (base case) $5.28M $9.76M $27.26M 51.6%
10.0% on guaranteed EV, rollover on equity $4.78M $9.76M $27.76M 52.6%
5.0% on headline EV, rollover on equity $2.64M $9.76M $29.90M 56.6%
15.0% on headline EV, rollover on equity $7.92M $9.76M $24.62M 46.6%
10.0% on headline EV, rollover on EV $5.28M $10.56M $26.46M 50.1%

Reading a buyer's "cash at close" percentage

FOCUS Investment Banking's Dermatology Practice Valuation: 2026 Benchmarks reports that platform-ready dermatology practices, typically targeting $5M+ of EBITDA, often receive "70%+ cash at close with meaningful rollover equity." Two limits apply before you hold your offer against it.

Question FOCUS 2026 benchmark Our worked example
Population Platform-ready dermatology practices, typically $5M+ EBITDA One hypothetical multi-specialty practice, $6.0M EBITDA
Deal definition Platform deals with meaningful rollover Any sale with rollover, earnout and escrow as entered
Denominator Not broken out line by line in the benchmark Headline EV
Treatment of escrow and earnout Not broken out line by line in the benchmark Shown as separate lines

The benchmark is specialty-specific and describes the strongest sellers, so use it as a directional check, not a target. What it does show is how far the ratio moves with definitions. Our example is 71.1% of headline after rollover and before the earnout and escrow, and 51.6% after both. A buyer quoting "70% cash" may mean either. Ask for the closing payment in dollars, with the denominator and every deduction written out.

Which Multiple to Plug In

Use the multiple in your LOI. If you are still pre-LOI, build a range with the practice valuation calculator and the valuation multiples guide, then run the calculator at the low, middle and high ends. Three facts shape where your number lands: what kind of deal you are in, what your revenue looks like and how the underlying spending is growing.

Most PE-backed healthcare deals are add-ons, not platforms. The Private Equity Stakeholder Project's 2025 in Review tracked 1,029 PE-backed healthcare deals announced in 2025, using PitchBook and LevinPro HC data, and notes that the final count is likely an underestimate.

PE-backed healthcare deals, 2025 (PESP) Count Share (our arithmetic)
Add-on acquisitions 664 64.5%
Growth investments 214 20.8%
Leveraged buyouts 151 14.7%
Total 1,029 100.0%
Platform companies involved 420 n/a
Investment firms involved 708 n/a

By subsector, PESP counted health IT at 151 PE deals in 2025, dental at 149, outpatient care at 148, medtech at 117 and behavioral health at 56. Within outpatient care, Becker's ASC Review, reporting PESP's 2025 data, puts 119 of the 148 deals as add-ons, 80.4% by our arithmetic. Dermatology led the outpatient subsectors with 24 deals, followed by eye care with 22 and oncology with 9.

An add-on prices off the platform's appetite for your EBITDA, not off the platform's own multiple. Expect the buyer to cite its platform's scale as the reason to roll equity, and expect your cash multiple to sit below the platform's.

Payer mix moves price and structure. FOCUS's 2026 dermatology benchmarks report that buyers prize practices with more than 70% commercial or cash-pay revenue, because that mix signals revenue quality, faster collections and protection from government reimbursement cuts. A practice below that line should expect buyers to push value into earnout and rollover. The national mix explains why. Per the CMS National Health Expenditure fact sheet, private health insurance accounted for $1,644.6 billion (31%) of 2024 US health spending and Medicare for $1,118.0 billion (21%). A practice whose revenue leans on government rates sits closer to reimbursement decisions it cannot influence.

Spending growth supports demand, not your specific multiple. The same CMS fact sheet reports that physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and projects it to grow 5.5% a year on average from 2025 through 2034. That is the backdrop buyers underwrite. Your multiple still turns on your own EBITDA quality, payer mix and deal type.

Record value at the top of the market is a large-deal statistic. The Bain & Company Global Healthcare Private Equity Report 2026 press release estimates a record $191 billion of global healthcare PE deal value in 2025, surpassing the 2021 peak. Provider and related services rose 57% to an estimated $62 billion, and healthcare IT within the provider segment doubled to an estimated $32 billion. Two methodology notes from Bain's physician group analysis matter here. Its 2025 figures are actual data through November 30, 2025, annualized for the rest of the year. Its deal count excludes add-on deals below $250 million. Bain's numbers therefore describe large transactions, while PESP's counts include the smaller add-ons most practice owners will sign. Bain also reports that physician group deal volumes have declined from their peak, even though the groups remain a major part of many PE portfolios. Record dollars at the top do not translate into a higher multiple for a mid-sized group.

Escrow and Indemnity: Model the Release, Not Just the Holdback

SRS Acquiom's 2026 Deal Terms for M&A Escrows covers deals across industries, not healthcare alone. Use it to set how often adjustments and claims happen in your stress cases. Use your LOI for the size of the holdback.

Adjustment and claim frequency (SRS Acquiom, 2026 report, all industries) Share
Deals with a purchase price adjustment (PPA) mechanism 93%
Of those, deals with an actual adjustment 89%
All deals with an actual adjustment (our arithmetic, 93% x 89%) about 83%
All deals with indemnification claims, excluding PPAs 28%

Weighing RWI. A reps and warranties policy lets a buyer accept a smaller escrow because the insurer covers losses above a retention. The gain is cash at closing instead of cash at release, plus claims shifted to the insurer. Claims below the retention stay with whoever funds it.

Example (our arithmetic, labeled assumptions): escrow of $5.28M without RWI or $1.00M with RWI, release at 18 months and an 8% annual discount rate. On the claim side, a 28% chance of a claim (SRS's all-industry frequency), a $1.5M claim if one occurs and a $0.5M retention funded by you. The model assumes any claim fits inside the no-RWI escrow and that the policy covers the full loss above the retention, with no exclusions. The 28% is an all-industry rate and the claim size and retention are assumptions, so the result is highly scenario-dependent. Healthcare billing and coding claims are commonly excluded, which means this example understates what a healthcare seller can keep on the hook.

Component Arithmetic Value
Escrow freed at closing $5.28M - $1.00M $4.28M
Time value of $4.28M held 18 months $4.28M x (1 - 1 / 1.08^1.5) $0.47M
Expected claims shifted to the insurer 28% x ($1.5M - $0.5M retention) $0.28M
Break-even for your premium share Sum of the two lines above $0.75M

On these assumptions, RWI improves your outcome if your share of the premium comes in under $0.75M. Larger claims, a lower retention or a longer escrow period all raise the break-even. Policy exclusions cut the other way. Any loss the policy excludes stays with you and comes out of the claims line. Ask whether billing, coding and reimbursement matters are excluded or carved into a special indemnity, because in healthcare those are the claims most likely to arise.

Questions for the buyer before you accept an escrow number:

The healthcare deal structures guide covers how indemnity caps and escrow terms interact, and the LOI and term sheet red flags checklist lists the escrow language to push back on.

Earnouts: Compare Offers on Cash, Not Multiple

Earnouts are measured under the buyer's ownership, on the buyer's systems and often under the buyer's accounting choices. Start dates, measurement periods and metrics are all negotiated. The calculator asks for your probability because nobody else's applies to your deal. Use the earnout value calculator to discount it for time.

The standard trade: the buyer concedes your headline multiple and recovers value through structure. When a buyer accepts your number, ask in the same conversation which terms changed, put each one in the LOI and compare offers line by line.

Example (illustrative, our arithmetic): Offer A is the 8.8x deal above. Offer B is 8.0x with no earnout and the same net debt, costs, 20% equity rollover and 10.0% escrow on EV.

Line Offer A: 8.8x, $5.0M earnout inside Offer B: 8.0x, no earnout
Headline EV $52.80M $48.00M
Equity value $48.80M $44.00M
Rollover at cost (20% of equity) $9.76M $8.80M
Escrow (10.0% of EV) $5.28M $4.80M
Cash at close $27.26M $28.90M
Baseline: cash after full escrow release, earnout excluded $32.54M $33.70M
Expected cash, full escrow back, earnout at 50% $35.04M $33.70M

The lower multiple puts $1.64M more in your hands at closing. The crossover uses the baseline row, which excludes the earnout. Offer A's $32.54M baseline trails Offer B's $33.70M by $1.16M, so Offer A matches Offer B on expected cash when its earnout probability equals ($33.70M - $32.54M) / $5.0M, or 23.2%. Above 23.2%, A wins on undiscounted expected cash. Below it, B wins. At the 50% probability used in the worked example, A's expected cash is $35.04M. Offer A also rolls $0.96M more into illiquid equity, because its rollover is computed on equity value that still contains the earnout. A seller who needs liquidity now, or who doubts the buyer's post-closing reporting, should demand a probability well above 23.2% before choosing A, since its extra money arrives later and depends on someone else's management.

Get written answers before you sign:

Rollover and Preferred Equity: What a 20% Stake Is Worth at 3 Exit Values

Rollover value depends on a sale you do not control and on where your shares sit in the payout order. Model the preference waterfall, not just the exit multiple. The calculator has no preferred-equity field. Do not fold a preference into net debt. Preferences can be fixed or accruing, participating or not, and convertible, so run them as a separate step.

At closing (illustrative). Your practice entity has issued preferred equity with a $6.0M non-participating preference, and the holders take the preference rather than convert. From the $48.80M equity value, $6.0M goes to preferred first, leaving $42.80M for common. Your charter and the purchase agreement govern how costs, escrow and rollover are then split between classes, so build that waterfall line by line before you sign.

After closing (illustrative, our arithmetic). Your $9.76M rollover buys 4% of a platform's common equity, implying $244M of common value at entry. A sponsor holds preferred with a fixed $300M preference, paid before common and non-participating. Total platform equity at entry is $544M.

Platform equity at exit Paid to preferred Left for common Your 4% vs $9.76M at cost
$400M (26% below entry) $300M $100M $4.00M down 59%
$544M (same as entry) $300M $244M $9.76M unchanged
$700M (29% above entry) $300M $400M $16.00M up 64%

The preference magnifies both directions. A 26% fall in platform equity costs your stake 59%, and a 29% rise lifts it 64%.

Accruing variant. Make the same preference accrue at 8% a year, compounded, with exit in year four. The preference grows to $300M x 1.08^4, or $408.1M. At a flat $544M exit, common receives $135.9M and your 4% is $5.44M, down 44% from cost on a platform that held its value. Your break-even exit rises to $408.1M + $244M, or $652.1M, 19.9% above entry. Run your own terms in the rollover equity calculator.

Rollover is an investment, not just a deferral. When you exchange practice equity for platform units, you are buying into the platform, and the buyer will paper it like an investment. That is why an investor questionnaire shows up in the closing set. Diligence the platform the way an investor would. Search its name and its holding company in SEC EDGAR full-text search, which shows whether the platform has filed notices of private capital raises before. The capital raising guide explains the paperwork behind a rollover, and the questions it raises belong with your own attorney.

Ask the buyer to fill in the tables above with real terms, and get answers to these:

The physician rollover equity checklist has the full list.

Larger Deals and Health System Buyers

Platform recapitalizations and large group sales can trigger regulatory review, and a review affects proceeds twice. Any filing cost goes into transaction costs, and the review period can push back your cash. Build the timing into your closing date and your personal liquidity plan. The healthcare M&A process guide walks through when reviews come up and how they affect the sequence. Raise timing and structure questions with your own attorney.

Sellers whose buyer is a health system may face a financially pressured counterparty. Kaufman Hall's Q3 2026 M&A report, released October 13, 2026, describes large health systems continuing to pursue deals amid ongoing industry transformation. Kaufman Hall tracks hospital operating margins separately in its National Hospital Flash Report, so check the latest edition before you negotiate. Becker's Hospital Review, reporting Kaufman Hall data, counts 56 hospital transactions announced through Q3 2026, against 46 in all of 2025. A health system under margin pressure protects its cash. Expect pressure on escrow, earnout and payment timing more than on the headline.

Before the LOI Call: 8 Terms to Pin Down in Dollars

Bring this table to every buyer conversation. Each row is a term that moved real money in the $52.8M worked example. Ask the buyer to state each one in dollars, then run the calculator again with their answers.

Term to get in writing What to ask for Worked-example figure Dollar swing in the example
Earnout placement "Including" or "plus" the headline $5.0M inside a $52.8M headline Guaranteed price of $47.8M vs $52.8M
Escrow base Guaranteed EV, not headline EV $5.28M on headline EV $0.50M more cash at close on guaranteed EV
Escrow rate The rate and any separate adjustment escrow 10.0% 5.0% to 15.0% moves cash at close from $29.90M to $24.62M
Rollover base Equity value, after the earnout comes out $9.76M on equity value $0.80M between cash and rolled equity
Net debt schedule Every loan and lease paid from proceeds $4.00M Each $1.00 cuts cash at close by $0.80
Working-capital peg The peg amount and how it was set $0 adjustment A $500K shortfall costs $400K cash and $100K rollover
Transaction costs Written quotes, including your RWI share $1.50M RWI pays off below a $0.75M premium share
Earnout odds Your own probability, not the buyer's 50% Offer A beats Offer B only above 23.2%

Run three cases before you answer the buyer. Each uses figures already worked out above.

Case What changes Cash at close Cash after escrow release Share of headline after release
Base Full escrow back, earnout excluded $27.26M $32.54M 61.6%
Moderate downside $500K working-capital shortfall $26.86M $32.14M 60.9%
Hard downside $500K shortfall, a quarter of escrow lost to a claim, earnout never paid $26.86M $30.82M 58.4%

If the hard downside still covers your debts, taxes and personal liquidity needs, the offer clears the first test. If it does not, negotiate the escrow base, rollover base and earnout placement before you negotiate the multiple. In this example those three terms together move more cash at closing than a half-turn of EBITDA.

If the buyer plans to acquire a management company rather than your clinical entity, the price and what you are actually selling can change. The management services organizations guide explains the model.

Closing Week: Tie the Funds Flow Memo Back to Your Model

The buyer's funds flow memo is the document that actually moves money. It lists every wire on closing day, and it is usually drafted by the buyer's side. Ask for the draft several business days before closing, open the calculator with your final terms and check each line against it. In the worked example, the memo should reconcile like this:

Funds flow line Worked-example figure What to check
Purchase price $52.80M Matches the LOI headline, with the $5.0M earnout shown as contingent, not paid
Debt payoffs $4.00M Each lender's payoff letter matches your net debt schedule, with interest run to the actual closing date
Estimated working-capital adjustment $0.00M The estimate uses the same accounts and method as the peg
Seller transaction expenses $1.50M Every invoice paid from your proceeds is yours, not the buyer's or the platform's
Rollover $9.76M Units issued at the agreed price equal rollover at cost, on the agreed base
Escrow deposit $5.28M Rate, base, escrow agent and release dates match the purchase agreement
Wire to seller $27.26M Ties to your calculator output within rounding, to the account you confirmed by phone

Any gap larger than rounding has a cause. The usual ones are a payoff letter with fees you did not schedule, a buyer expense charged to the seller column or an escrow percentage applied to a different base. Resolve each one before you sign the closing statement, because the post-closing true-up only revisits working capital.

Map the money to dates, not just amounts. The $52.8M headline arrives in four pieces on four timelines, pre-tax:

When it arrives Worked-example amount What can reduce it
Closing day $27.26M Payoff surprises and expense reallocations caught too late
Escrow release (18 months in the RWI example) Up to $5.28M Claims and adjustments: $3.96M if a quarter is consumed
End of the earnout period Up to $5.00M Missed targets and offsets: $2.50M at a 50% probability
Platform sale $9.76M at cost The preference waterfall: $4.00M to $16.00M in the exit table

Build your personal plan on the closing-day row alone. Set aside your estimated tax on the full transaction from that $27.26M with your tax adviser, since some of the tax can fall due before the escrow or earnout money arrives. Treat the other three rows as upside you plan around, not cash you spend.

Questions Practice Owners and Investors Ask

How much of the sale price do I actually receive at closing when I sell a medical practice?

Less than the headline. Cash at close is EBITDA times the multiple, less net debt, plus or minus the working-capital adjustment, then minus transaction costs, rollover, any earnout inside the headline and escrow. In our illustrative $6M EBITDA example, $27.26M of the $52.8M headline, or 51.6%, arrives at closing, pre-tax. Escrow and the earnout come later or not at all, and rollover stays illiquid until the platform sells.

A buyer says I will get 70% cash at close. What should I ask?

Ask what the 70% is measured against and what has already come out. The ratio changes with the denominator (headline EV, guaranteed EV or equity value) and with whether escrow and the earnout are counted as cash. In our worked example the same deal is 71.1% of headline after rollover but before earnout and escrow, and 51.6% after both. Get the closing payment in dollars, not as a percentage.

Should I count an earnout as part of my sale price?

Count it as contingent consideration. First confirm whether the LOI headline contains it. If $5.0M of a $52.8M headline is earnout, the guaranteed price on $6.0M of EBITDA is $47.8M, or 7.97x, not 8.8x. Then enter your own probability of collecting it and compare offers on cash at close and expected cash, not on the multiple.

Does the calculator account for taxes, preferred equity or a seller note?

No. Every output is pre-tax. Preferred equity ahead of your common and any seller note sit outside the formula. Run a preference as a separate waterfall step, as in the rollover section, and subtract a seller note from cash at close yourself because it is deferred cash with credit risk.

What EBITDA multiple should I use for my practice?

Use the multiple in your LOI. Without one, build a range with the practice valuation calculator and the valuation multiples guide and run the low, middle and high cases. Most PE-backed healthcare deals are add-ons, and an add-on generally prices below a platform. The 8.8x in our worked example is an assumption, not a benchmark.

Sources